Sepsis Opportunity Guanine’s initial clinical focus on sepsis with a rapid 20 minute host response, 60 minute pathogen ID and 90 minute culture-free phenotyping presents a compelling, time-sensitive diagnostic workflow. Business development can target hospital systems, ICU networks, and emergency departments seeking faster antimicrobial stewardship and improved patient outcomes.

OEM Expansion The platform is designed for OEM integration to accelerate assay development and reduce system cost and complexity. Salesforce conversations should emphasize partnerships with diagnostic manufacturers and device integrators looking to add high-plex, multiplex electrochemical sensing capabilities into their existing portfolios.

Multi-Omic Advantage A single scalable electrochemical architecture enables simultaneous measurement of proteins, metabolites, nucleic acids, and drug response. This broad multiplexing capability opens cross-portfolio sales with infectious disease, chronic disease diagnostics, and precision health AI applications, appealing to diversified partner ecosystems.

Clinical Collaboration Active collaboration with Mount Sinai Health Systems and ongoing clinical engagement indicate a readiness to validate and pilot in real-world settings. Use these relationships to co-create value propositions around early actionable insights, which can attract tiered pilot programs and larger integration deals.

Global Scaling The platform targets point-of-care to high-throughput laboratory formats and OEM deployments, offering a path to global scalability. Sales discussions can highlight flexible deployment models, international regulatory readiness, and support for rapid expansion with strategic distributors and clinical partners.